Total Ideas
1
Bullish Ideas
0 (0%)
Bearish Ideas
Recent Activity
0
"SPRO: Suffered setbacks with Tebipenem - net royalty 0% on first $750M sales, milestone reduced from $150M to $101M. Pro forma cash ~$55M to last into 2028. CEO sees Tebipenem as main value driver, decision on IV720 by mid-2026. Risk-reward looks decent at low $2s with ~$2.40 mid-case fair value."
Sentiment